[Clinical study on cinobufotalin in treating chronic hepatitis B virus carriers].

Abstract

In a preliminary study, carriers of hepatitis B virus were treated with Cinobufotalin, a preparation from toad, for 1-3 course of treatment. Results indicated that negative conversion rate was markedly higher in the treated groups (21.09%, 38.89%, 63.64% and 50%) than that of control groups (2.1%, 10.87%, 33.33% and 7.7% P < 0.001). By the end of treatment, positive conversion rate of anti-HBs and anti-HBe were also markedly higher in the former (19.29% and 23.45%) than that in the latter (4.26% and 7.14% P < 0.001). During the follow-up of 3-6 months, the positive rate of HBeAg in treated group (50%) raised as compared with the control group (20% P = 0.08). The results indicated that Cinobufotalin had a significant effect in inhibiting the replication of HBV.

• Authors: X T Xu
• Journal: Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine (Zhongguo Zhong Xi Yi Jie He Za Zhi) Vol. 13 Issue 8 Pg. 473-5, 453-4 (Aug 1993) ISSN: 1003-5370 [Print] China
• PMID: 8111200 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)

Chemical References

• Bufanolides
• Hepatitis B Antibodies
• Hepatitis B Surface Antigens
• Hepatitis B e Antigens
• Materia Medica
• cinobufotalin

Topics

• Bufanolides (therapeutic use)
• Carrier State (drug therapy)
• Female
• Hepatitis B (drug therapy)
• Hepatitis B Antibodies (blood)
• Hepatitis B Surface Antigens (blood)
• Hepatitis B e Antigens (blood)
• Humans
• Male
• Materia Medica (therapeutic use)